• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在瑞士血色素沉着症队列中,血色素沉着症诊断时年龄较大是肝细胞癌发生的最强预测因素:一项前瞻性纵向观察研究。

Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study.

作者信息

Nowak Albina, Giger Rebekka S, Krayenbuehl Pierre-Alexandre

机构信息

Department of Endocrinology and Clinical Nutrition, University Hospital Zurich.

Department of Internal Medicine, Psychiatric University Hospital Zurich, University of Zurich.

出版信息

Medicine (Baltimore). 2018 Oct;97(42):e12886. doi: 10.1097/MD.0000000000012886.

DOI:10.1097/MD.0000000000012886
PMID:30335010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6211894/
Abstract

Hereditary hemochromatosis (HH) is the most common genetic disease in Caucasians which is characterized by an increased intestinal iron absorption, resulting into a progressive accumulation of iron in organs including liver, heart, and pancreas, leading to their progressive dysfunction. Hepatocellular carcinoma (HCC) is a long-term complication of HH, which contributes to increased mortality.We evaluated the risk factors of HCC in a prospective cohort of Swiss hemochromatosis patients with a long-term follow-up.We included 147 patients with the mean age at diagnosis of 48 years, in whom 70% were men. Overall, 9% of the patients developed HCC during the mean follow-up time of 14 years (range 1-40 years). Patients with HCC had higher age at diagnosis (61 ± 11 vs 47 ± 13 years, P = .003), more frequently liver cirrhosis on biopsy (90% vs 37.5%, P = .004), and higher serum ferritin levels [3704 (Q1:2025, Q3:4463) vs 1338 (Q1:691, Q3:2468) μg/L, P < .001], they needed more iron removed by phlebotomy until its depletion [8.9 (Q1:7.2, Q3:10.1) vs 3.8 (Q1:1.6, Q3:8.9) g, P = .029], compared to non-HCC patients. After adjustment for possible confounders, only higher age at diagnosis remained significantly associated with HCC development (odds ratio 1.19, 95% CI 0.056-0.397, P = .001, per year).Higher age at diagnosis showed the strongest association with the occurrence of HCC in Swiss hemochromatosis patients. Patients who were diagnosed at a higher age and with a high iron overload (serum ferritin levels >1000 μg/L) require regular screening even if they have no liver cirrhosis.

摘要

遗传性血色素沉着症(HH)是白种人中最常见的遗传性疾病,其特征是肠道铁吸收增加,导致铁在肝脏、心脏和胰腺等器官中逐渐积累,进而导致这些器官功能逐渐失调。肝细胞癌(HCC)是HH的一种长期并发症,会导致死亡率上升。我们对一组进行长期随访的瑞士血色素沉着症患者前瞻性队列进行研究,评估了HCC的危险因素。我们纳入了147例患者,诊断时的平均年龄为48岁,其中70%为男性。总体而言,在平均14年(范围1 - 40年)的随访时间里,9%的患者发生了HCC。发生HCC的患者诊断时年龄更大(61±11岁 vs 47±13岁,P = 0.003),活检时肝硬化的发生率更高(90% vs 37.5%,P = 0.004),血清铁蛋白水平更高[3704(四分位间距Q1:2025,Q3:4463)vs 1338(Q1:691,Q3:2468)μg/L,P < 0.001],与未发生HCC的患者相比,他们需要通过放血去除更多的铁直至铁耗竭[8.9(Q1:7.2,Q3:10.1)vs 3.8(Q1:1.6,Q3:8.9)g,P = 0.029]。在对可能的混杂因素进行校正后,仅诊断时年龄较大仍与HCC发生显著相关(比值比1.19,95%置信区间0.056 - 0.397,P = 0.001,每年)。在瑞士血色素沉着症患者中,诊断时年龄较大与HCC发生的关联最强。诊断时年龄较大且铁过载严重(血清铁蛋白水平>1000μg/L)的患者即使没有肝硬化也需要定期筛查。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c325/6211894/152be4c86471/medi-97-e12886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c325/6211894/152be4c86471/medi-97-e12886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c325/6211894/152be4c86471/medi-97-e12886-g001.jpg

相似文献

1
Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study.在瑞士血色素沉着症队列中,血色素沉着症诊断时年龄较大是肝细胞癌发生的最强预测因素:一项前瞻性纵向观察研究。
Medicine (Baltimore). 2018 Oct;97(42):e12886. doi: 10.1097/MD.0000000000012886.
2
[Idiopathic hemochromatosis].[特发性血色素沉着症]
Minerva Med. 1985 Mar 31;76(13):627-34.
3
Hepatocellular carcinoma in non-cirrhotic liver without evidence of iron overload in a patient with primary hemochromatosis. Review.一名原发性血色素沉着症患者非肝硬化肝脏中的肝细胞癌,无铁过载证据。综述。
J Gastrointest Cancer. 2012 Mar;43(1):36-9. doi: 10.1007/s12029-010-9205-5.
4
Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.在诊断时血清铁蛋白水平大于 1000μg/L 的 422 例 HFE 血色病治疗先证者中,铁过载导致死亡的风险增加。
Clin Gastroenterol Hepatol. 2012 Apr;10(4):412-6. doi: 10.1016/j.cgh.2011.11.032. Epub 2012 Jan 17.
5
Hepatocellular carcinoma associated with hereditary hemochromatosis occurring in non-cirrhotic liver.遗传性血色素沉着症相关的肝细胞癌发生于非肝硬化肝脏。
Z Gastroenterol. 2006 Jan;44(1):39-42. doi: 10.1055/s-2005-858567.
6
Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis.血清透明质酸联合血清铁蛋白可准确预测C282Y型血色素沉着症患者的肝硬化情况,并减少肝脏活检的必要性。
Hepatology. 2009 Feb;49(2):418-25. doi: 10.1002/hep.22650.
7
An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma-a case report.一个不幸的三联征:血色素沉着症、迟发性皮肤卟啉症和肝细胞癌——一例报告
World J Gastroenterol. 2007 Apr 7;13(13):1998-2001. doi: 10.3748/wjg.v13.i13.1998.
8
Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention.
Med Clin North Am. 2005 Mar;89(2):391-409. doi: 10.1016/j.mcna.2004.08.005.
9
Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis.肝硬化逆转后特发性血色素沉着症中的原发性肝细胞癌
Gastroenterology. 1988 Nov;95(5):1399-402. doi: 10.1016/0016-5085(88)90379-4.
10
Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis.遗传性血色素沉着症合并肝硬化患者的预后因素与生存率
Can J Gastroenterol. 2006 Apr;20(4):257-60. doi: 10.1155/2006/428048.

引用本文的文献

1
The Quiet Burden of Iron: A Rare Case of Hereditary Hemochromatosis in Pakistan.铁的隐匿负担:巴基斯坦一例罕见的遗传性血色素沉着症病例
Cureus. 2025 Jul 20;17(7):e88355. doi: 10.7759/cureus.88355. eCollection 2025 Jul.
2
Quantitative and qualitative analysis of quality of life in people diagnosed with genetic haemochromatosis in the United Kingdom.英国遗传性血色素沉着症患者生活质量的定量与定性分析
J Patient Rep Outcomes. 2025 Jul 29;9(1):96. doi: 10.1186/s41687-025-00865-6.
3
Hepatic Iron Overload and Hepatocellular Carcinoma: New Insights into Pathophysiological Mechanisms and Therapeutic Approaches.

本文引用的文献

1
The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.全身铁稳态机制以及遗传性血色素沉着症的病因、诊断和治疗
Int J Hematol. 2018 Jan;107(1):31-43. doi: 10.1007/s12185-017-2365-3. Epub 2017 Nov 13.
2
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
3
The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.
肝铁过载与肝细胞癌:病理生理机制及治疗方法的新见解
Cancers (Basel). 2025 Jan 24;17(3):392. doi: 10.3390/cancers17030392.
4
Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.代谢性肝病相关肝细胞癌发病机制的研究进展
J Hepatocell Carcinoma. 2024 Mar 19;11:581-594. doi: 10.2147/JHC.S450460. eCollection 2024.
5
Haemochromatosis patients' research priorities: Towards an improved quality of life.血色病患者的研究重点:提高生活质量。
Health Expect. 2023 Dec;26(6):2293-2301. doi: 10.1111/hex.13830. Epub 2023 Jul 28.
6
Guideline Review: European Association for the Study of Liver (EASL) Clinical Practice Guidelines on Haemochromatosis.指南综述:欧洲肝脏研究协会(EASL)血色病临床实践指南
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):649-655. doi: 10.1016/j.jceh.2022.11.003. Epub 2022 Nov 11.
7
The Effects of Dandelion Polysaccharides on Iron Metabolism by Regulating Hepcidin JAK/STAT Signaling Pathway.蒲公英多糖通过调控铁调素 JAK/STAT 信号通路对铁代谢的影响。
Oxid Med Cell Longev. 2021 Jan 2;2021:7184760. doi: 10.1155/2021/7184760. eCollection 2021.
8
Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy.肝脏介导的耐受在基于纳米颗粒的肿瘤治疗中的作用。
Cells. 2020 Aug 28;9(9):1985. doi: 10.3390/cells9091985.
9
Juvenile Hemochromatosis: A Case Report and Review of the Literature.青少年血色素沉着症:一例病例报告及文献综述
Pharmaceuticals (Basel). 2020 Aug 15;13(8):195. doi: 10.3390/ph13080195.
10
Hemochromatosis in India: First Report of Whole Exome Sequencing With Review of the Literature.印度的血色素沉着症:全外显子测序的首例报告及文献综述
J Clin Exp Hepatol. 2020 Mar-Apr;10(2):163-169. doi: 10.1016/j.jceh.2019.04.051. Epub 2019 Apr 29.
与HFE基因C282Y和H63D突变相关的新发癌症风险:来自87,028名参与者的证据。
J Cell Mol Med. 2016 Jul;20(7):1219-33. doi: 10.1111/jcmm.12764. Epub 2016 Feb 19.
4
Alcoholic liver disease--epidemiology and risk factors.酒精性肝病——流行病学与危险因素
Rev Med Chir Soc Med Nat Iasi. 2014 Oct-Dec;118(4):910-7.
5
Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.红细胞单采术与全血采血术治疗遗传性血色素沉着症的比较。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s84-9. doi: 10.2450/2013.0128-13. Epub 2013 Oct 23.
6
Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies.慢性肝病中肝细胞癌的监测:证据与争议。
World J Gastroenterol. 2013 Oct 28;19(40):6744-56. doi: 10.3748/wjg.v19.i40.6744.
7
Iron and cancer: more ore to be mined.铁与癌症:更多的关联有待挖掘。
Nat Rev Cancer. 2013 May;13(5):342-55. doi: 10.1038/nrc3495. Epub 2013 Apr 18.
8
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.非酒精性脂肪性肝病相关肝细胞癌:一种新出现的威胁。
J Hepatol. 2012 Jun;56(6):1384-91. doi: 10.1016/j.jhep.2011.10.027. Epub 2012 Feb 9.
9
Management of hepatocellular carcinoma: an update.肝细胞癌的管理:最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
10
Role of iron in carcinogenesis: cancer as a ferrotoxic disease.铁在致癌作用中的角色:癌症作为一种铁中毒性疾病。
Cancer Sci. 2009 Jan;100(1):9-16. doi: 10.1111/j.1349-7006.2008.01001.x. Epub 2008 Oct 23.